The present invention is directed to radiolabeled pyrimidinone compounds of general structural formula I which are useful as radiotracers for quantitative imaging of PDE10 in mammals.
-
(2019/07/13)
Discovery of [11C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors
Phosphodiesterase 10A (PDE10A) inhibition has recently been identified as a potential mechanism to treat multiple symptoms that manifest in schizophrenia. In order to facilitate preclinical development and support key proof-of-concept clinical trials of novel PDE10A inhibitors, it is critical to discover positron emission tomography (PET) tracers that enable plasma concentration/PDE10A occupancy relationships to be established across species with structurally diverse PDE10A inhibitors. In this Letter, we describe how a high-throughput screening hit was optimized to provide [11C]MK-8193 (8j), a PET tracer that supports the determination of plasma concentration/PDE10A occupancy relationships for structurally diverse series of PDE10A inhibitors in both rat and rhesus monkey.
Cox, Christopher D.,Hostetler, Eric D.,Flores, Broc A.,Evelhoch, Jeffrey L.,Fan, Hong,Gantert, Liza,Holahan, Marie,Eng, Waisi,Joshi, Aniket,McGaughey, Georgia,Meng, Xiangjun,Purcell, Mona,Raheem, Izzat T.,Riffel, Kerry,Yan, Youwei,Renger, John J.,Smith, Sean M.,Coleman, Paul J.
p. 4893 - 4898
(2015/10/28)
PYRIMIDINONES AS PDE10 INHIBITORS
The present invention is directed to pyrimidinone compounds of general structural formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10).
-
Page/Page column 48-49
(2010/12/26)
More Articles about upstream products of 1256450-59-5